Skip to main content

Table 3 Ongoing clinical trials evaluating new anti-HER2 molecules combined with hormone therapy in first-line setting

From: First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Trial Phase Treatment Primary Objective
PERTAIN II Trastuzumab + Pertuzumab + AI vs Trastuzumab + AI PFS
DETECT V/CHEVENDO III Trastuzumab + Pertuzumab + CT vs Trastuzumab + Pertuzumab + HTa Safety
1303GCC II Trastuzumab + Pertuzumab vs Trastuzumab + Pertuzumab + Eribulin vs Trastuzumab + Pertuzumab + HT b ORr
  1. AI aromatase hinibitor, CT chemotherapy (docetaxel, paclitaxel, capecitabine, vinorelbine), aHT: Hormonal Therapy (tamoxifen, fulvestrant, letrozole, exemestane or anastrozole); bHT: Hormonal Therapy (anastrozolo or fulvestrant); PFS: Progression Free Survival; ORr: Overall Response rate